Anti-cancer and anti-radiation drugs

We are an emerging pharmaceutical company focused on anti-cancer and anti-radiation drugs. The lead cancer drug, BP-C1, has successfully completed pivotal clinical trials in metastatic breast cancer. Clinical trials of the agent in pancreas cancer, where it demonstrates promising intermediate results, will continue to bladder and prostate cancers. The lead anti-radiation drug, BP-C2, can clinically be used to protect and treat radiation-induced injuries. BP-C2 as a prophylaxis and treatment of radiation induced damages in cancer treatment in both oral and topical administrations is soon entering phase I clinical trials. We are interested to identify and discuss possible collaboration with potential Israeli partners in: • Non-clinical trials and clinical trials in various cancer types as well regarding anti-radiation injuries • Commercial opportunities with relevant entities What we are looking for: Private enterprises and scientific institutions with expertise in • Cancer • Anti-Radiation • Health Economics • Regulatory Affairs